PROMIS NEUROSCIENCES HIGHLIGHTS DATA FOR PMN310 AT AAIC 2019

TORONTO, Ontario and CAMBRIDGE, Mass. —July 18, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s Association International Conference® (AAIC) in Los Angeles. MORE>>